Cargando…
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern
Severe Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting...
Autores principales: | Valdovino-Navarro, Blanca J., Dueñas, Salvador, Flores-Acosta, G. Isaí, Gasperin-Bulbarela, Jahaziel, Bernaldez-Sarabia, Johanna, Cabanillas-Bernal, Olivia, Cervantes-Luevano, Karla E., Licea-Navarro, Alexei F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603574/ https://www.ncbi.nlm.nih.gov/pubmed/36293124 http://dx.doi.org/10.3390/ijms232012267 |
Ejemplares similares
-
Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico
por: Cervantes-Luevano, Karla, et al.
Publicado: (2022) -
COVID-19 Neutralizing Antibodies in Breast Milk of Mothers Vaccinated with Three Different Vaccines in Mexico
por: Cabanillas-Bernal, Olivia, et al.
Publicado: (2022) -
Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2
por: Cabanillas-Bernal, Olivia, et al.
Publicado: (2023) -
First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment
por: Burciaga-Flores, Mirna, et al.
Publicado: (2023) -
Chimeric Peptides from Californiconus californicus and Heterodontus francisci with Antigen-Binding Capacity: A Conotoxin Scaffold to Create Non-Natural Antibodies (NoNaBodies)
por: Dueñas, Salvador, et al.
Publicado: (2023)